• Royalty Pharma EVP and Chairman, Partnering Christopher Hite sold 130,000 Class A ordinary shares on June 30.
• Sales included 100,000 shares held indirectly through SCH Investment Partners, leaving 459,399 shares indirectly owned.
• Another 30,000 shares were sold from direct holdings, leaving 40,000 shares directly owned.
• Reported weighted-average sale prices ranged from $56.44 to $57.10 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royalty Pharma plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001814238-26-000011), on July 02, 2026, and is solely responsible for the information contained therein.